Table 1. Selected characteristics of cases and controls.
| Characteristic | Casesa | Controlsa |
|---|---|---|
| Patients | 178 (100) | 358 (100) |
| Cohort | ||
| ATBC | 59 (33.2) | 117 (32.7) |
| CPS-II | 67 (37.6) | 135 (37.7) |
| MCCS | 52 (29.2) | 106 (29.6) |
| Sex | ||
| Female | 49 (27.5) | 100 (27.9) |
| Male | 129 (72.5) | 258 (72.1) |
| Mean (s.d.) age at blood draw | 63.0 (7.8) | 63.0 (7.8) |
| Mean (s.d.) BMI at blood draw, kg/m2 | 26.9 (4.0) | 26.5 (4.2) |
| Type of blood sample | ||
| EDTA | 67 (37.6) | 135 (37.7) |
| Heparin plasma | 52 (29.2) | 106 (29.6) |
| Serum | 59 (33.2) | 117 (32.7) |
| Time from blood draw to diagnosis | ||
| <7 years | 85 (47.8) | |
| ⩾7 years | 93 (52.3) | |
| Median resistin concentrationb (IQR) | ||
| Overall | 5.47 (4.08–7.11) | 5.82 (4.47–7.37) |
| Female | 6.24 (5.11–8.44) | 5.88 (4.48–7.66) |
| Male | 5.20 (3.93–6.46)c | 5.82 (4.44–7.33) |
Abbreviations: ATBC=Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; BMI=body mass index; CPS-II=the Cancer Prevention Study II; IQR=interquartile range; MCCS=Melbourne Collaborative Cohort Study.
a
Reported as N (%) unless otherwise noted.
b
On the basis of corrected resistin levels in ng ml−1 (Supplementary Methods).
c
Wilcoxon two-sample test P=0.006.